Efficacy and safety of ospemifene in the treatment of vulvar and vaginal atrophy (VVA) in postmenopausal women: a 12-week, randomized, double-blind, parallel-group study comparing oral ospemifene 30 and 60 mg daily doses with placebo.

Trial Profile

Efficacy and safety of ospemifene in the treatment of vulvar and vaginal atrophy (VVA) in postmenopausal women: a 12-week, randomized, double-blind, parallel-group study comparing oral ospemifene 30 and 60 mg daily doses with placebo.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Apr 2015

At a glance

  • Drugs Ospemifene (Primary)
  • Indications Atrophic vaginitis; Menopausal syndrome
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Most Recent Events

    • 04 Jul 2013 Last checked against ClinicalTrials.gov record (extension study NCT01586364).
    • 04 Jul 2013 Last checked against ClinicalTrials.gov record (extension study NCT01586364).
    • 04 Jul 2013 Last checked against ClinicalTrials.gov record (extension study NCT01586364).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top